Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics
July 29 2020 - 9:11AM
Business Wire
TrueBinding signs multi-product commercial-use
license to develop stable, antibody-expressing cell lines using
Horizon’s gene-edited CHO GS knockout platform
Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company”
or “the Group”), a global leader in the application of gene editing
and gene modulation for cell line engineering, today announced that
TrueBinding, Inc. (“TrueBinding”, formerly Immutics, Inc.), a
biopharmaceutical company, has signed a set of commercial licenses
for Horizon’s cGMP-compliant CHOSOURCE™ platform. TrueBinding will
use the platform for the development and commercialization of
multiple biotherapeutic products for applications in
immuno-oncology and other disease areas with great unmet medical
need.
Horizon’s CHOSOURCE platform includes a gene-edited Glutamine
Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell
line, a well-established GS expression system recognized in the
industry and by regulators as suitable for high-yield
biomanufacturing. TrueBinding has successfully used this platform
to develop stable, antibody-expressing cell lines in a
proof-of-concept study and will now implement this to support
further antibody drug development through commercial
manufacturing.
“We are delighted TrueBinding has placed its trust in the
capabilities of Horizon’s CHOSOURCE expression platform to support
its research and development efforts,” commented Jesús Zurdo,
Global Head Bioproduction Business Unit, Horizon Discovery.
“Horizon is fully committed to supporting innovative organizations
of all sizes, from non-profit organizations and early stage
startups to clinical stage biotechnology and large pharmaceutical
companies, in their journey to develop much-needed novel
therapeutic products using our expression platform.”
Dr. Fan Chen, SVP of CMC, TrueBinding, explained:
“Horizon’s CHOSOURCE platform provides a robust system for
generating high protein expression stable cell lines to support
TrueBinding antibody drug development through commercial
manufacturing. We are very pleased with current program results and
move to further collaboration with Horizon Discovery.”
Horizon’s proprietary GS knockout CHO line and protocols
facilitate the development of stable cell lines for the expression
of antibodies and other recombinant proteins. The Company also
licenses a CHO expression system to pharmaceutical, biotechnology,
and biosimilar companies, as well as contract manufacturing
organizations. To enable companies to move from the DNA sequence of
their potential biotherapeutic to clinical manufacturing as simply
and rapidly as possible, the complete system includes the GS
knockout CHO K1 cell line, a comprehensive package of supporting
documentation, and an expression vector supplied under license from
DNATwoPointO, Inc.
To date, CHOSOURCE has been licensed to 80 organizations
globally, with at least seven confirmed biotherapeutics expressed
in these cells having progressed to investigational new drug (IND)
filings.
For further information on Horizon’s CHO expression system
please visit:
https://www.horizondiscovery.com/bioproduction/cho-cells
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200729005647/en/
Zyme Communications (Trade and Regional Media) Lorna
Cuddon Tel: +44 (0)7811 996 942 Email:
lorna.cuddon@zymecommunications.com
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024